Liu Cunbao, Yao Yufeng, Yang Xu, Bai Hongmei, Huang Weiwei, Xia Ye, Ma Yanbing
Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan 650118, P.R. China.
J Microbiol Biotechnol. 2015 Jun;25(6):936-40. doi: 10.4014/jmb.1412.12027.
Human papillomavirus (HPV) type 52 is a high-risk HPV responsible for cervical cancer. HPV type 52 is common around the world and is the most common in some Asian regions. The available prophylactic HPV vaccines protect only from HPV types 16 and 18. Supplementing economical vaccines that target HPV type 52 may satisfactorily complement available prophylactic vaccines. A codon-adapted HPV 52 L1 gene was expressed in the methylotrophic yeast Hansenula polymorpha, which is used as an industrial platform for economical hepatitis B surface antigen particle production in China. We found that the recombinant proteins produced in this expression system could form virus-like particles (VLPs) with diameters of approximately 50 nm. This study suggests that the HPV 52 VLPs produced in this platform may satisfactorily complement available prophylactic vaccines in fighting against HPVs prevalent in Asia.
人乳头瘤病毒52型（HPV-52）是导致宫颈癌的高危型人乳头瘤病毒。HPV-52在全球范围内普遍存在，在一些亚洲地区最为常见。现有的预防性HPV疫苗仅能预防16型和18型HPV。补充针对HPV-52型的经济型疫苗可能会令人满意地补充现有的预防性疫苗。一种密码子优化的HPV 52 L1基因在甲醇营养型酵母多形汉逊酵母中表达，在中国该酵母被用作生产经济型乙肝表面抗原颗粒的工业平台。我们发现，在该表达系统中产生的重组蛋白可以形成直径约为50 nm的病毒样颗粒（VLP）。这项研究表明，在该平台上产生的HPV 52 VLP在对抗亚洲流行的HPV方面可能会令人满意地补充现有的预防性疫苗。
